Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived.

Slides:

Advertisements

Similar presentations

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Advertisements

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Data-selection process

Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Schematic representation of the experimental design.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Mechanism of mortality benefit associated with radial access

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

AHA: American Heart Association; ALT: ...

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Source: Figure created by the author based on data ...

bDMARD: biologic DMARD.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

RCTs: randomized controlled ...

Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Take home figure The protective role of CNP/NPR-B/NPRC.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Fig. 1. A flowchart of cohort participants screened, enrolled and followed-up between 1 July 2015 and 31 May Fig. 1. A flowchart of cohort participants.

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Figure 1 Selection algorithm of patients being included in the German Aortic Valve Registry in 2014 and Figure 1 Selection algorithm of patients.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Relationships between pair indices of dance performance (joint entropy or mutual information) and the past ... Figure 1 Relationships between.

Figure 1. Flow diagram for selection of articles for systematic review. Unless provided in the caption above, the following copyright applies to the content.

Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ... Figure 1. Time–kill studies for selected.

Figure 1 Immunohistochemistry for human cell differentiation molecules in samples of the right ventricular septum from ... Figure 1 Immunohistochemistry.

Figure 1. Results of search based on the PRISMA statement.14

Figure 1. Percentage of Pacific and European children completing all components of B4SC in 2013 and 2015 Figure 1. Percentage of Pacific and European.

Figure 1 MIC test strips showing reversion of daptomycin resistance of isolate 5 passaged in vitro. This figure ... Figure 1 MIC test strips showing reversion.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure Ranking of Cardiovascular Journals as published by Clarivate Analytics. Unless provided in the caption above, the following copyright applies.

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Patient selection

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

Fig. 1 A network representation of top 100 co-occurring terms

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Statistics of the main characters’ dialogues.

Figure 1 Patient selection.

Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.

The figure shows the fraction of ...

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Schematic subcategorization of AAV in three clinically relevant disease categories defined by clinical ... Fig. 1 Schematic subcategorization of.

Figure 3. Key words and phrases from narrative text by classification category. Unless provided in the caption above, the following copyright applies to.

Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia ... Fig. 1: World distribution of.

Figure 1. A summary of phase 3 trials for previously untreated advanced/metastatic NSCLC. AEs, adverse events; Beva, ... Figure 1. A summary of phase 3.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1: Trade shares of South Korea's major trading partners (% of South Korea's total trade in goods) Figure 1: Trade shares of South Korea's major.

Figure 1. Kaplan Meier curves showing crude product limit survival estimates and 95% confidence intervals for time to ... Figure 1. Kaplan Meier curves.

Figure 1. Measuring respondent unhappiness with their child marrying someone from the other party and happiness with ... Figure 1. Measuring respondent.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Evolutionary process of a policy field.

Table 2. Mean noise level results for hand dryers in dBA

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Figure 1. Kaplan–Meier curves showing the impact of the different pretreatment HIV-1 drug resistance categories on the ... Figure 1. Kaplan–Meier curves.

Presentation transcript:

Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves with the first-stage intervention ibrutinib plus obinutuzumab (IO) and the second-stage intervention ibrutinib maintenance (IM), for all simulated patients and for subgroups of simulated patients who did and did not achieve minimal residual disease negative with complete response (MRD- CR) status. (B) Kaplan–Meier curves with first-stage intervention ibrutinib plus venetoclax plus obinutuzumab (IVO) and second-stage intervention IM or IM discontinuation, for all simulated patients and for subgroups of simulated patients who did and did not achieve MRD- CR status. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Ann Oncol, Volume 30, Issue 4, 25 February 2019, Pages 542–550, https://doi.org/10.1093/annonc/mdz053 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 1. SMART Schema. Both randomizations (R) use the use the initial stratification factors of baseline Rai stage ... Figure 1. SMART Schema. Both randomizations (R) use the use the initial stratification factors of baseline Rai stage (intermediate versus high) and FISH abnormality del(17)(p13.1) at baseline (present versus absent). Ibrutinib maintenance (IM) in stage 2 continues until disease progression, death, or unacceptable adverse events. Patients randomized to IM discontinuation would not receive any ibrutinib therapy following re-randomization. Embedded treatment regimen (1, 1) includes patients randomized to ibrutinib plus obinutuzumab followed by IM, regardless of minimal residual disease negative with complete response (MRD- CR) status; embedded treatment regimen (2, 1) includes patients randomized to ibrutinib plus venetoclax plus obinutuzumab followed by IM, regardless of MRD- CR status; embedded treatment regimen (2, 2) includes patients randomized to ibrutinib plus venetoclax plus obinutuzumab followed by IM for those who do not achieve MRD- CR status and IM discontinuation for those who do achieve MRD- CR status. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Ann Oncol, Volume 30, Issue 4, 25 February 2019, Pages 542–550, https://doi.org/10.1093/annonc/mdz053 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3. Kaplan–Meier curves for each embedded treatment regimen, derived from data generated under study-specific ... Figure 3. Kaplan–Meier curves for each embedded treatment regimen, derived from data generated under study-specific assumptions. Embedded treatment regimen (1, 1) includes simulated patients in the ibrutinib plus obinutuzumab (IO) arm with ibrutinib maintenance (IM); embedded treatment regimen (2, 1) includes simulated patients in the ibrutinib plus venetoclax plus obinutuzumab (IVO) arm with IM, regardless of minimal residual disease negative with complete response (MRD- CR) status; embedded treatment regimen (2, 2) includes simulated patients in the IVO arm with IM for those who did not achieve MRD- CR status and IM discontinuation for those who did achieve MRD- CR status. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Ann Oncol, Volume 30, Issue 4, 25 February 2019, Pages 542–550, https://doi.org/10.1093/annonc/mdz053 The content of this slide may be subject to copyright: please see the slide notes for details.